silodosin ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
4151 160970-54-7

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • silodosin
  • urief
  • urorec
  • rapaflo
  • silodyx
  • silodoshin
an alpha(1a)-adrenoceptor-selective antagonist; structure given in first source
  • Molecular weight: 495.54
  • Formula: C25H32F3N3O4
  • CLOGP: 3.16
  • LIPINSKI: 0
  • HAC: 7
  • HDO: 3
  • TPSA: 97.05
  • ALOGS: -4.65
  • ROTB: 14

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
8 mg O

ADMET properties:

PropertyValueReference
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.23 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 32 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
CL (Clearance) 2.80 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.05 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 3.60 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Jan. 29, 2010 EMA
Oct. 8, 2008 FDA ACTAVIS LABS UT INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Haematoma 57.74 44.50 14 132 30496 50574482

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Urinary retention 82.61 14.37 80 11272 31818 29531357
Granulomatous rosacea 52.22 14.37 12 11340 137 29563038
Interstitial lung disease 48.94 14.37 83 11269 57635 29505540
Retrograde ejaculation 47.50 14.37 13 11339 313 29562862
Orthostatic hypotension 42.81 14.37 48 11304 22581 29540594
Mucosal dryness 39.96 14.37 15 11337 1014 29562161
Hyponatraemia 37.26 14.37 81 11271 67552 29495623
Hypoparathyroidism 34.31 14.37 11 11341 463 29562712
Toxicity to various agents 34.22 14.37 12 11340 173649 29389526
Pemphigoid 33.87 14.37 26 11326 7555 29555620
Histamine level increased 33.16 14.37 7 11345 52 29563123
Cerebellar ischaemia 32.79 14.37 8 11344 120 29563055
Left atrial dilatation 32.75 14.37 15 11337 1678 29561497
Haematocrit increased 32.62 14.37 15 11337 1693 29561482
Cerebral haematoma 31.58 14.37 20 11332 4276 29558899
Acute kidney injury 31.33 14.37 191 11161 265076 29298099
Cerebral infarction 30.07 14.37 42 11310 24633 29538542
Fall 27.88 14.37 138 11214 177040 29386135
Presyncope 26.85 14.37 32 11320 16057 29547118
Acute lung injury 26.38 14.37 12 11340 1321 29561854
Ejaculation failure 25.55 14.37 10 11342 757 29562418
Haemoglobin increased 25.20 14.37 15 11337 2871 29560304
Tryptase increased 24.67 14.37 7 11345 193 29562982
Loss of consciousness 24.36 14.37 73 11279 73983 29489192
Tongue oedema 24.15 14.37 14 11338 2552 29560623
Reversible airways obstruction 23.10 14.37 7 11345 244 29562931
Lactic acidosis 22.38 14.37 41 11311 30206 29532969
Subdural haematoma 22.21 14.37 31 11321 18162 29545013
Face oedema 21.50 14.37 23 11329 10260 29552915
Angle closure glaucoma 21.44 14.37 9 11343 816 29562359
Acquired haemophilia 21.26 14.37 9 11343 834 29562341
Blood triglycerides decreased 21.23 14.37 5 11347 64 29563111
Lymphopenia 21.09 14.37 26 11326 13507 29549668
Neutrophil percentage decreased 20.75 14.37 7 11345 346 29562829
Neuropathy vitamin B6 deficiency 20.60 14.37 3 11349 0 29563175
Hepatic function abnormal 20.45 14.37 46 11306 39213 29523962
Hypoproteinaemia 20.42 14.37 11 11341 1741 29561434
Rash vesicular 19.65 14.37 12 11340 2406 29560769
Eosinophilia 18.93 14.37 32 11320 22129 29541046
Band neutrophil percentage increased 18.87 14.37 5 11347 106 29563069
Atrioventricular block complete 18.69 14.37 19 11333 7992 29555183
Eosinophil percentage increased 18.21 14.37 7 11345 505 29562670
Mucocutaneous disorder 18.20 14.37 5 11347 122 29563053
Bradycardia 18.20 14.37 61 11291 65568 29497607
Arrhythmia 17.79 14.37 38 11314 31275 29531900
Altered state of consciousness 17.36 14.37 29 11323 19860 29543315
Hepatocellular injury 17.26 14.37 30 11322 21213 29541962
Multiple drug therapy 16.65 14.37 6 11346 361 29562814
Decreased appetite 16.04 14.37 103 11249 145239 29417936
Adenocarcinoma gastric 15.94 14.37 8 11344 1095 29562080
Haematuria 15.94 14.37 45 11307 44094 29519081
Pneumonia aspiration 15.84 14.37 40 11312 36697 29526478
Acidosis 15.69 14.37 19 11333 9686 29553489
Cardiac failure 15.58 14.37 66 11286 79221 29483954
Tricuspid valve disease 15.56 14.37 5 11347 212 29562963
Erectile dysfunction 15.37 14.37 26 11326 17983 29545192
Wrong patient received product 15.23 14.37 10 11342 2272 29560903
Band neutrophil count increased 14.96 14.37 5 11347 240 29562935
Platelet count decreased 14.66 14.37 79 11273 104593 29458582
Dermatitis exfoliative 14.55 14.37 15 11337 6410 29556765

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Urinary retention 88.04 16.71 68 10020 49133 64439511
Acute kidney injury 64.05 16.71 184 9904 449056 64039588
Interstitial lung disease 62.98 16.71 77 10011 97655 64390989
Granulomatous rosacea 58.91 16.71 12 10076 197 64488447
Retrograde ejaculation 58.08 16.71 12 10076 212 64488432
Hyponatraemia 48.76 16.71 85 10003 148254 64340390
Orthostatic hypotension 40.57 16.71 43 10045 46695 64441949
Cerebral infarction 39.66 16.71 40 10048 41004 64447640
Left atrial dilatation 38.63 16.71 15 10073 2751 64485893
Mucosal dryness 37.45 16.71 15 10073 2986 64485658
Pemphigoid 37.32 16.71 24 10064 12962 64475682
Histamine level increased 36.48 16.71 7 10081 83 64488561
Haematocrit increased 35.87 16.71 15 10073 3330 64485314
Cerebral haematoma 33.06 16.71 18 10070 7167 64481477
Subdural haematoma 32.09 16.71 30 10058 28024 64460620
Presyncope 29.94 16.71 32 10056 35057 64453587
Toxicity to various agents 29.59 16.71 10 10078 363503 64125141
Haemoglobin increased 29.54 16.71 15 10073 5186 64483458
Haematuria 28.64 16.71 41 10047 60430 64428214
Acute lung injury 28.46 16.71 12 10076 2719 64485925
Bradycardia 28.03 16.71 59 10029 118160 64370484
Lactic acidosis 26.72 16.71 40 10048 61370 64427274
Reversible airways obstruction 26.49 16.71 9 10079 1129 64487515
Cardiac failure 25.70 16.71 61 10027 132312 64356332
Decreased appetite 25.44 16.71 99 9989 281190 64207454
Tryptase increased 25.09 16.71 7 10081 455 64488189
Hypoparathyroidism 24.58 16.71 8 10080 879 64487765
Prostate cancer 24.25 16.71 22 10066 19773 64468871
Pain 23.89 16.71 31 10057 553480 63935164
Anaemia 23.44 16.71 119 9969 378561 64110083
Acquired haemophilia 23.39 16.71 9 10079 1611 64487033
Neuropathy vitamin B6 deficiency 23.29 16.71 3 10085 0 64488644
Eosinophilia 22.89 16.71 29 10059 38047 64450597
Haematoma 22.85 16.71 32 10056 46218 64442426
Hepatic function abnormal 22.60 16.71 38 10050 64275 64424369
Mucocutaneous disorder 22.25 16.71 5 10083 133 64488511
Neutrophil percentage decreased 21.87 16.71 7 10081 729 64487915
Face oedema 21.87 16.71 23 10065 24738 64463906
Cerebellar ischaemia 21.67 16.71 5 10083 150 64488494
Benign prostatic hyperplasia 21.66 16.71 15 10073 9150 64479494
Platelet count decreased 21.21 16.71 66 10022 167645 64320999
Lymphopenia 21.19 16.71 23 10065 25634 64463010
Arrhythmia 20.94 16.71 33 10055 52911 64435733
Blood triglycerides decreased 20.93 16.71 5 10083 175 64488469
Pneumonia aspiration 20.80 16.71 35 10053 59236 64429408
Fall 20.44 16.71 123 9965 416703 64071941
Hepatocellular injury 20.44 16.71 30 10058 45205 64443439
Hypoproteinaemia 19.93 16.71 10 10078 3372 64485272
Atrioventricular block complete 19.61 16.71 17 10071 14401 64474243
Tongue oedema 19.54 16.71 12 10076 5978 64482666
Angle closure glaucoma 19.10 16.71 9 10079 2648 64485996
Rash vesicular 19.05 16.71 11 10077 4899 64483745
Hyperkalaemia 18.97 16.71 46 10042 101083 64387561
Acidosis 18.40 16.71 18 10070 17777 64470867
Altered state of consciousness 18.39 16.71 26 10062 37876 64450768
Hypokalaemia 18.30 16.71 51 10037 121852 64366792
Rhabdomyolysis 17.50 16.71 42 10046 91684 64396960
Erectile dysfunction 17.40 16.71 15 10073 12612 64476032
Eosinophil percentage increased 17.36 16.71 7 10081 1417 64487227
Tricuspid valve disease 17.07 16.71 5 10083 387 64488257
Pneumonia bacterial 17.04 16.71 16 10072 15019 64473625
Band neutrophil percentage increased 16.94 16.71 5 10083 397 64488247
Atrial fibrillation 16.92 16.71 62 10026 171027 64317617
Arthralgia 16.86 16.71 27 10061 442233 64046411
Agranulocytosis 16.76 16.71 25 10063 38204 64450440

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC G04CA04 GENITO URINARY SYSTEM AND SEX HORMONES
UROLOGICALS
DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY
Alpha-adrenoreceptor antagonists
FDA MoA N0000000099 Adrenergic alpha-Antagonists
FDA EPC N0000175553 alpha-Adrenergic Blocker
MeSH PA D018663 Adrenergic Agents
MeSH PA D058668 Adrenergic alpha-1 Receptor Antagonists
MeSH PA D000317 Adrenergic alpha-Antagonists
MeSH PA D018674 Adrenergic Antagonists
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D064804 Urological Agents

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Benign prostatic hyperplasia indication 266569009
Orthostatic hypotension contraindication 28651003
Acute nephropathy contraindication 58574008
Hepatic failure contraindication 59927004
Kidney disease contraindication 90708001 DOID:557
Cataract surgery contraindication 110473004
Intraoperative floppy iris syndrome contraindication 418801006




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 13.41 acidic
pKa2 7.96 Basic
pKa3 4.09 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Alpha-1A adrenergic receptor GPCR ANTAGONIST Ki 10.44 CHEMBL CHEMBL
Potassium voltage-gated channel subfamily H member 2 Ion channel IC50 5.09 CHEMBL
Multidrug resistance protein 1 Transporter WOMBAT-PK
Alpha-1D adrenergic receptor GPCR ANTAGONIST Ki 8.70 IUPHAR
Alpha-1B adrenergic receptor GPCR ANTAGONIST Ki 7.70 IUPHAR
Alpha-1A adrenergic receptor GPCR IC50 9.10 CHEMBL

External reference:

IDSource
4028100 VUID
N0000177928 NUI
D01965 KEGG_DRUG
4028100 VANDF
C1870115 UMLSCUI
CHEBI:135929 CHEBI
CHEMBL24778 ChEMBL_ID
DB06207 DRUGBANK_ID
C095285 MESH_SUPPLEMENTAL_RECORD_UI
493 IUPHAR_LIGAND_ID
8043 INN_ID
CUZ39LUY82 UNII
5312125 PUBCHEM_CID
720825 RXNORM
159000 MMSL
26009 MMSL
299655 MMSL
d07354 MMSL
012969 NDDF
441605002 SNOMEDCT_US
442042006 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
RAPAFLO HUMAN PRESCRIPTION DRUG LABEL 1 0023-6142 CAPSULE 8 mg ORAL NDA 26 sections
RAPAFLO HUMAN PRESCRIPTION DRUG LABEL 1 0023-6147 CAPSULE 4 mg ORAL NDA 26 sections
Silodosin HUMAN PRESCRIPTION DRUG LABEL 1 0781-2623 CAPSULE, GELATIN COATED 4 mg ORAL ANDA 26 sections
Silodosin HUMAN PRESCRIPTION DRUG LABEL 1 0781-2624 CAPSULE, GELATIN COATED 8 mg ORAL ANDA 26 sections
Silodosin Human Prescription Drug Label 1 27241-144 CAPSULE 4 mg ORAL ANDA 25 sections
Silodosin Human Prescription Drug Label 1 27241-145 CAPSULE 8 mg ORAL ANDA 25 sections
Silodosin Human Prescription Drug Label 1 31722-635 CAPSULE 4 mg ORAL ANDA 28 sections
Silodosin Human Prescription Drug Label 1 31722-636 CAPSULE 8 mg ORAL ANDA 28 sections
Silodosin Human Prescription Drug Label 1 33342-384 CAPSULE 4 mg ORAL ANDA 26 sections
Silodosin Human Prescription Drug Label 1 33342-385 CAPSULE 8 mg ORAL ANDA 26 sections
Silodosin Human Prescription Drug Label 1 46708-405 CAPSULE 4 mg ORAL ANDA 25 sections
Silodosin Human Prescription Drug Label 1 46708-406 CAPSULE 8 mg ORAL ANDA 25 sections
RAPAFLO HUMAN PRESCRIPTION DRUG LABEL 1 54868-6173 CAPSULE 8 mg ORAL NDA 24 sections
SILODOSIN Human Prescription Drug Label 1 59651-095 CAPSULE 4 mg ORAL ANDA 26 sections
SILODOSIN Human Prescription Drug Label 1 59651-096 CAPSULE 8 mg ORAL ANDA 26 sections
Silodosin HUMAN PRESCRIPTION DRUG LABEL 1 60219-1420 CAPSULE 8 mg ORAL ANDA 25 sections
Silodosin HUMAN PRESCRIPTION DRUG LABEL 1 60219-1421 CAPSULE 4 mg ORAL ANDA 25 sections
Silodosin Human Prescription Drug Label 1 62332-405 CAPSULE 4 mg ORAL ANDA 26 sections
Silodosin Human Prescription Drug Label 1 62332-406 CAPSULE 8 mg ORAL ANDA 26 sections
Silodosin HUMAN PRESCRIPTION DRUG LABEL 1 68180-740 CAPSULE 4 mg ORAL ANDA 24 sections
Silodosin HUMAN PRESCRIPTION DRUG LABEL 1 68180-741 CAPSULE 8 mg ORAL ANDA 24 sections
Silodosin HUMAN PRESCRIPTION DRUG LABEL 1 69238-1420 CAPSULE 8 mg ORAL ANDA 25 sections
Silodosin HUMAN PRESCRIPTION DRUG LABEL 1 69238-1421 CAPSULE 4 mg ORAL ANDA 25 sections
SILODOSIN Human Prescription Drug Label 1 69539-052 CAPSULE 4 mg ORAL ANDA 26 sections
SILODOSIN Human Prescription Drug Label 1 69539-053 CAPSULE 8 mg ORAL ANDA 26 sections
SILODOSIN Human Prescription Drug Label 1 72205-009 CAPSULE 4 mg ORAL ANDA 26 sections
SILODOSIN Human Prescription Drug Label 1 72205-010 CAPSULE 8 mg ORAL ANDA 26 sections
SILODOSIN HUMAN PRESCRIPTION DRUG LABEL 1 72789-090 CAPSULE 8 mg ORAL ANDA 26 sections
SILODOSIN HUMAN PRESCRIPTION DRUG LABEL 1 72789-090 CAPSULE 8 mg ORAL ANDA 26 sections